Graham and Angus update the latest research and views on weight loss drugs. This episode dives deep into the evolving science behind GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). While these medications offer unprecedented results in fat loss and metabolic improvement, they also come with emerging concerns—especially around bone density, muscle loss, and long-term safety. They break down current trial data, potential risks for non-obese users, and crucial strategies to mitigate side effects through targeted nutrition, resistance training, and lifestyle changes.

Ver todos los episodios